

AMENDMENTS TO THE CLAIMS

1. (Currently amended) A method of treating a patient afflicted with **a-neoplastic cancer a cancer selected from the group consisting of breast, head, neck, esophageal, lung, and colon cancer**, the method comprising oral administration of a pharmaceutical composition to the patient, the pharmaceutical composition consisting essentially of

- (a) a taxane;
- (b) a solvent capable of dissolving the taxane;
- (c) polyoxyethylated castor oil;
- (d) a diluent; and
- (e) optionally, a flavoring;

wherein the taxane has a solubility in ethanol at room temperature of at least 200 mg/ml.

2. (Original) The method of claim 1 wherein the composition contains a flavoring.

3. (Original) The method of claim 1 wherein the solvent capable of dissolving the taxane is ethanol.

4. (Original) The method of claim 1 wherein the diluent is water, saline, dextrose or an electrolyte solution.

5. (Original) The method of claim 1 wherein the solvent capable of dissolving the taxane is ethanol and the diluent is saline.

6. (Original) The method of claim 5 wherein the ethanol and polyoxyethylated castor oil are present in a volumetric ratio of about 1 to 1.

7. (Currently amended) The method of claim 1 wherein the taxane has an ID_{50} value determined relative to **[[the]] an** HCT116 cell line that is at least 4 times less than that of paclitaxel.

8. (Currently amended) The method of claim 1 wherein the taxane has an ID_{50} value determined relative to **[[the]] an** HCT116 cell line that is at least 7 times less than that of paclitaxel.

9. (Currently amended) The method of claim 1 wherein the taxane has an ID_{50} value determined relative to **[[the]] an** HCT116 cell line that is at least 10 times less than that of paclitaxel.

10. (Original) The method of claim 1 wherein the taxane has a solubility in ethanol at room temperature of at least 500 mg/ml.

11. (Original) The method of claim 1 wherein the taxane has a solubility in ethanol at room temperature of at least 800 mg/ml.

12. (Currently amended) The method of claim 10 wherein the taxane has an ID_{50} value determined relative to **[[the]] an** HCT116 cell line that is at least 4 times less than that of paclitaxel.

13. (Currently amended) The method of claim 10 wherein the taxane has an ID_{50} value determined relative to **[[the]] an** HCT116 cell line that is at least 7 times less than that of paclitaxel.

14. (Currently amended) The method of claim 10 wherein the taxane has an ID_{50} value determined relative to **[[the]] an** HCT116 cell line that is at least 10 times less than that of paclitaxel.

15. (Currently amended) The method of claim 11 wherein the taxane has an ID₅₀ value determined relative to ~~[[the]]~~ an HCT116 cell line that is at least 4 times less than that of paclitaxel.

16. (Currently amended) The method of claim 11 wherein the taxane has an ID₅₀ value determined relative to ~~[[the]]~~ an HCT116 cell line that is at least 7 times less than that of paclitaxel.

17. (Currently amended) The method of claim 11 wherein the taxane has an ID₅₀ value determined relative to ~~[[the]]~~ an HCT116 cell line that is at least 10 times less than that of paclitaxel.

18. (New) The method of claim 1 wherein the cancer is breast cancer.

19. (New) The method of claim 1 wherein the cancer is esophagus cancer.

20. (New) The method of claim 1 wherein the cancer is colon cancer.